Obesity & Metabolic Syndrome Unit, Division of Endocrinology & Metabolism, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil.
Expert Rev Clin Pharmacol. 2013 May;6(3):235-41. doi: 10.1586/ecp.13.13.
The aim of this article is to focus on the fixed-dose combination of phentermine and topiramate, a new antiobesity drug recently approved by the US FDA. The mechanisms of weight loss for each drug in monotherapy is described, followed by the rationale for its use as a combination therapy and a comprehensive review of recently published clinical trials that assessed its efficacy and safety.
本文旨在关注最近获得美国 FDA 批准的一种新型减肥药——苯丁胺和托吡酯的固定剂量组合。本文先描述了每种药物单药治疗时的减肥机制，接着阐述了将其作为联合疗法使用的原理，最后对最近评估其疗效和安全性的临床试验进行了全面回顾。
